Cogent Biosciences (COGT) EBITDA (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of EBITDA data on file, last reported at -$103.6 million in Q1 2026.

• On a quarterly basis, EBITDA fell 38.27% year-over-year to -$103.6 million in Q1 2026; TTM through Mar 2026 was -$362.0 million, a 25.5% decrease from a year earlier, with the FY2025 full-year figure at -$333.4 million, down 20.81% from the prior year.
• EBITDA for Q1 2026 stood at -$103.6 million, down from -$99.5 million in the prior quarter.
• Over the last five years, EBITDA for COGT reached as high as -$31.4 million in Q1 2022 and fell as low as -$103.6 million in Q1 2026.
• Historically, EBITDA has averaged -$62.9 million across 5 years, with a median of -$62.4 million in 2024.
• Across the five-year window, EBITDA sank 145.45% in 2022 and retreated 10.53% in 2025, its largest moves.
• Year by year, EBITDA stood at -$43.7 million in 2022, then tumbled by 33.11% to -$58.2 million in 2023, then dropped by 26.63% to -$73.7 million in 2024, then sank by 34.94% to -$99.5 million in 2025, then fell by 4.13% to -$103.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$103.6 million in Q1 2026, -$99.5 million in Q4 2025, and -$83.4 million in Q3 2025.